BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 27312795)

  • 21. Targeted Mutational Profiling Reveals Clonal Relationships in Metachronous Occurrence of Classic Hodgkin and Mediastinal Large B-Cell Lymphomas.
    Singh K; Lezama LS; Kurzer J; Oak J; Schultz LM; Walkush A; Cheng TC; Chen EH; May WA; Chang C; Link MP; Advani RH; Suarez CJ; Natkunam Y
    Am J Surg Pathol; 2023 Jan; 47(1):81-90. PubMed ID: 36001451
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma.
    Rosenwald A; Wright G; Leroy K; Yu X; Gaulard P; Gascoyne RD; Chan WC; Zhao T; Haioun C; Greiner TC; Weisenburger DD; Lynch JC; Vose J; Armitage JO; Smeland EB; Kvaloy S; Holte H; Delabie J; Campo E; Montserrat E; Lopez-Guillermo A; Ott G; Muller-Hermelink HK; Connors JM; Braziel R; Grogan TM; Fisher RI; Miller TP; LeBlanc M; Chiorazzi M; Zhao H; Yang L; Powell J; Wilson WH; Jaffe ES; Simon R; Klausner RD; Staudt LM
    J Exp Med; 2003 Sep; 198(6):851-62. PubMed ID: 12975453
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic and therapeutic significance of XPO1 in T-cell lymphoma.
    Nie D; Xiao X; Chen J; Xie S; Xiao J; Yang W; Liu H; Wang J; Ma L; Du Y; Huang K; Li Y
    Exp Cell Res; 2022 Jul; 416(2):113180. PubMed ID: 35489384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. XPO1 blockade with KPT-330 promotes apoptosis in cutaneous T-cell lymphoma by activating the p53-p21 and p27 pathways.
    Chakravarti N; Boles A; Burzinski R; Sindaco P; Isabelle C; McConnell K; Mishra A; Porcu P
    Sci Rep; 2024 Apr; 14(1):9305. PubMed ID: 38653804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome.
    Bledsoe JR; Redd RA; Hasserjian RP; Soumerai JD; Nishino HT; Boyer DF; Ferry JA; Zukerberg LR; Harris NL; Abramson JS; Sohani AR
    Am J Hematol; 2016 Oct; 91(10):E436-41. PubMed ID: 27419920
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary mediastinal B-cell lymphoma: hypermutation of the BCL6 gene targets motifs different from those in diffuse large B-cell and follicular lymphomas.
    Malpeli G; Barbi S; Moore PS; Scardoni M; Chilosi M; Scarpa A; Menestrina F
    Haematologica; 2004 Sep; 89(9):1091-9. PubMed ID: 15377470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human Exportin-1 is a Target for Combined Therapy of HIV and AIDS Related Lymphoma.
    Boons E; Vanstreels E; Jacquemyn M; Nogueira TC; Neggers JE; Vercruysse T; van den Oord J; Tamir S; Shacham S; Landesman Y; Snoeck R; Pannecouque C; Andrei G; Daelemans D
    EBioMedicine; 2015 Sep; 2(9):1102-13. PubMed ID: 26501108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. XPO1-dependent nuclear export as a target for cancer therapy.
    Azizian NG; Li Y
    J Hematol Oncol; 2020 Jun; 13(1):61. PubMed ID: 32487143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of DLBCL with a PMBL gene expression signature.
    Duns G; Viganò E; Ennishi D; Sarkozy C; Hung SS; Chavez E; Takata K; Rushton C; Jiang A; Ben-Neriah S; Woolcock BW; Slack GW; Hsi ED; Craig JW; Hilton LK; Shah SP; Farinha P; Mottok A; Gascoyne RD; Morin RD; Savage KJ; Scott DW; Steidl C
    Blood; 2021 Jul; 138(2):136-148. PubMed ID: 33684939
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heterozygous mutation of cysteine528 in XPO1 is sufficient for resistance to selective inhibitors of nuclear export.
    Neggers JE; Vanstreels E; Baloglu E; Shacham S; Landesman Y; Daelemans D
    Oncotarget; 2016 Oct; 7(42):68842-68850. PubMed ID: 27634897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53.
    Deng M; Zhang M; Xu-Monette ZY; Pham LV; Tzankov A; Visco C; Fang X; Bhagat G; Zhu F; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; Choi WWL; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; van Krieken JH; Piris MA; Winter JN; Hagemeister F; Alinari L; Li Y; Andreeff M; Xu B; Young KH
    J Hematol Oncol; 2020 Nov; 13(1):148. PubMed ID: 33148342
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma.
    Tanaka Y; Maeshima AM; Nomoto J; Makita S; Fukuhara S; Munakata W; Maruyama D; Tobinai K; Kobayashi Y
    Eur J Haematol; 2018 May; 100(5):511-517. PubMed ID: 29377256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.
    Green AL; Ramkissoon SH; McCauley D; Jones K; Perry JA; Hsu JH; Ramkissoon LA; Maire CL; Hubbell-Engler B; Knoff DS; Shacham S; Ligon KL; Kung AL
    Neuro Oncol; 2015 May; 17(5):697-707. PubMed ID: 25366336
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.
    Kashyap T; Argueta C; Aboukameel A; Unger TJ; Klebanov B; Mohammad RM; Muqbil I; Azmi AS; Drolen C; Senapedis W; Lee M; Kauffman M; Shacham S; Landesman Y
    Oncotarget; 2016 Nov; 7(48):78883-78895. PubMed ID: 27713151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia.
    Lapalombella R; Sun Q; Williams K; Tangeman L; Jha S; Zhong Y; Goettl V; Mahoney E; Berglund C; Gupta S; Farmer A; Mani R; Johnson AJ; Lucas D; Mo X; Daelemans D; Sandanayaka V; Shechter S; McCauley D; Shacham S; Kauffman M; Chook YM; Byrd JC
    Blood; 2012 Nov; 120(23):4621-34. PubMed ID: 23034282
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of XPO1 Overexpression with NF-κB and Ki67 in Colorectal Cancer.
    Aladhraei M; Kassem Al-Thobhani A; Poungvarin N; Suwannalert P
    Asian Pac J Cancer Prev; 2019 Dec; 20(12):3747-3754. PubMed ID: 31870117
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma.
    Gandhi UH; Senapedis W; Baloglu E; Unger TJ; Chari A; Vogl D; Cornell RF
    Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):335-345. PubMed ID: 29610030
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Verdinexor (KPT-335), a Selective Inhibitor of Nuclear Export, Reduces Respiratory Syncytial Virus Replication
    Jorquera PA; Mathew C; Pickens J; Williams C; Luczo JM; Tamir S; Ghildyal R; Tripp RA
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30541831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genomic Landscape of Primary Mediastinal B-Cell Lymphoma Cell Lines.
    Dai H; Ehrentraut S; Nagel S; Eberth S; Pommerenke C; Dirks WG; Geffers R; Kalavalapalli S; Kaufmann M; Meyer C; Faehnrich S; Chen S; Drexler HG; MacLeod RA
    PLoS One; 2015; 10(11):e0139663. PubMed ID: 26599546
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma.
    Mottok A; Hung SS; Chavez EA; Woolcock B; Telenius A; Chong LC; Meissner B; Nakamura H; Rushton C; Viganò E; Sarkozy C; Gascoyne RD; Connors JM; Ben-Neriah S; Mungall A; Marra MA; Siebert R; Scott DW; Savage KJ; Steidl C
    Blood; 2019 Sep; 134(10):802-813. PubMed ID: 31292115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.